Sativa Wellness Group submits its Novel Food application for validation by the FSA

Sativa Wellness Group plc (AQSE:SWEL) has announced that it has submitted its Novel Food application for validation by the Food Standards Agency ahead of the 31 March 2021 deadline, as part of the Company’s ongoing commitment to continually deliver the highest level of regulatory compliance and product quality – ‘CBD you can trust’.  

The submission, led by award winning Life Sciences Regulatory and Quality Compliance consultancy, Global Regulatory Services (“GRS”) and supported by Group’s in-house team of scientist and quality/compliance professionals, incorporates an extensive array of products under its Goodbody brands and on behalf of white label customers. Products include oil-based food supplements, gummies, soft gel capsules and sports recovery gels, as well as wholesale bulk CBD ingredients.

Further to the Company’s press release dated 25 September 2020, Sativa is also a member of the Association for the Cannabinoid Industry (ACI) Novel Food consortium and its landmark toxicology study, providing the necessary safety data required by the FSA.

The Company plans to submit the same application to the European Food Safety Authority, once it has collated the pre-requisite consumer product stability, toxicology and genotox data.

Geremy Thomas, Executive Chairman, said: “This is a significant milestone for the Company. The CBD market is likely to consolidate around the major players that put product quality and regulatory compliance at the forefront. Sales channels in the UK will open up and smaller players will likely fall away”.  

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn

More articles like this

Sativa Wellness Group Management Share Compensation Arrangements

Sativa Wellness Group plc (AQSE:SWEL / CNSX:SWEL) today announced certain management share compensation arrangements and amendments that have been approved by the Board of Directors with a view to both incentivising and aligning management and shareholder interests. Firstly, following

Use of Cannabidiol for the treatment of Anxiety

A macro-analysis of 49 different research papers (focusing primarily on animal studies) on the effects of CBD regarding multiple anxiety or stress-oriented disorders, such as Post-Traumatic Stress Disorder, Generalised Anxiety Disorder, and Social Anxiety Disorder to

The “Runner’s High” and Endocannabinoids

A runner’s high is a sense of well-being some people experience after prolonged exercise. For decades, it was hypothesized that exercise-induced endorphin release is solely responsible for a runner’s high, but recent evidence has suggested that

CBD bioavailability and why it matters

Wealth, friends, and even spouses, if lost, can be regained or acquired again somehow. But the body, once gone, will never come back- no matter how hard we try to revive the life that’s lost. Our

Finding relief from aches and pains

Everyone at some point of their life will experience some aches and pain, and it could be because of a whole range of different reasons. For some of us, that would be a bit of joint

CBD and mental health: A systematic analysis

There is a lot of research about the positive effects of CBD and Mental Health.  This report is a systematic analysis of a multitude of different research papers and conducted trials with regards to CBD’s impact

General benefits of CBD

CBD has been reported to help people in a number of ways. From pain relief, memory, and sleep to name a few, there’s a chance that we could all benefit from CBD in one way or

CBD and Diabetes: How can it help?

Close to 4.9 million people in the UK have been diagnosed with diabetes, with a further 850,000 people suspected to be living with undiagnosed type 2 diabetes. To add on to this, 13.6 million people in

The effects of cannabidiol on cerebral blood flow

The primary aim of this research paper was to investigate how CBD influences cerebral blood flow (CBF) in regions involved in memory processing. It was conducted under a randomised, crossover, double-blind design in which 15 healthy

Sativa Wellness Group Report record Q3 revenues (Interview)

Sativa Wellness Group Inc. (AQSE:SWEL / CNSX:SWEL) CEO Mark Howells joins DirectorsTalk Interviews to discuss a record quarterly profit in Q3 2021. Mark talks us through the numbers, explains how sustainable the performance is and plans